PYC THERAPEUTICS LIMITED — Director's Dealing 2020

Oct 27, 2020

ASX ANNOUNCEMENT 28 October 2020

==> picture [120 x 65] intentionally omitted <==

Change in Director’s Interest Notice x 2

PYC Therapeutics Limited (the ‘Company’) submits the following Appendix 3Y’s – Change in Director’s Interests, in relation to Alan Tribe and Bernard Hockings, from participation in the accelerated component of the non-renouceable entitlements issue.

This ASX announcement was approved and authorised for release by the Rohan Hockings CEO of PYC Therapeutics Limited.

ENDS For further information, please contact:

INVESTORS Rohan Hockings CEO info@pyctx.com This ASX announcement was approved and authorised for release by the B

oard of PYC Therapeutics Limited.

-Q

About PYC Therapeutics

PYC Therapeutics Limited (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

Tel: +61 8 6151 0994

pyctx.com

PYC Therapeutics Limited

ACN 098 391 961

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	PYC THERAPEUTICS LIMITED
ABN	48 098 391 961

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alan William Tribe
Date of last notice	15 June 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	INDIRECT
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Mr Tribe is a Director of Australian Land Pty Ltd,Delarge Investments Pty Ltd, Runcton Pty Ltd,Pagham Pty Ltd and Stockbridge Corporation PtyLtd.
Date of change	28 October 2020
No. of securities held prior to change	882,563,760 ordinary shares
Class	Ordinary shares
Number acquired	88,256,376 ordinary shares
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$0.17 per ordinary share
No. of securities held after change	970,820,136 ordinary shares

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback

Participation in accelerated component of nonrenounceable entitlements issue.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed

Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity PYC THERAPEUTICS LIMITED ABN 48 098 391 961

We, Phylogica Limited, give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

for the director for the purposes of section	205G of the Corporations Act.
Name of Director	Bernard Edward Frederick Hockings
Date of last notice	15 June 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

	Direct or indirect interest	Direct or indirect interest	Direct or indirect interest	Direct and Indirect	Direct and Indirect	Direct and Indirect	Direct and Indirect
	Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.			INDIRECTDr Bernard Edward Hockings &Mrs Dianne Christine Hockings(B Hockings Private S/F 2 A/C)
				g
	Date of change			28 October 2020
	No of securities held	rior to chane		DIRECT
	.	p g		- 103,3	51,783 Ordinary Shares
				INDIR	ECT
				- Dr Be	rnard Edward Hockings &
				Mrs D	ianne Christine Hockings
				(B Ho	ckings private S/F 2 A/C)
				156,5	2,436 Ordinary shares
	Class			Ordinary shares
	Number acquired			2,941,177
	Nature of changeExample: on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participation in buy-back			Participation in accelerated component ofnon-renounceable entitlement issue.

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$0.17 per share
No. of securities held after change	DIRECT- 105,392,960 Ordinary SharesINDIRECT- Dr Bernard Edward Hockings &Mrs Dianne Christine Hockings(B Hockings private S/F 2 A/C)157,442,436 Ordinary shares- Alexandra Hockings (Daughter)2,708,172 Ordinary shares- James Hockings (Son)1,057,180 Ordinaryshares

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011